Peiguo Cao

机构：Central South University, Third Xiangya Hospital · ORCID：0000-0002-8828-9755

发表论文 114 篇 · 总被引 3236 次 · h-index 25

代表论文

• Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer (2022 · JAMA · 被引 498)
• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 455)
• Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study (2023 · The Lancet Respiratory Medicine · 被引 77)
• Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial (2022 · British Journal of Cancer · 被引 33)
• Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study (2022 · Journal of Thoracic Oncology · 被引 26)
• A feedback loop between GATA2-AS1 and GATA2 promotes colorectal cancer cell proliferation, invasion, epithelial-mesenchymal transition and stemness via recruiting DDX3X (2022 · Journal of Translational Medicine · 被引 25)